The platform, dubbed MnO2–R848@CM, was developed by Zhen Zhang of Sun Yat-sen University and colleagues working across institutions in China, including the Hong Kong University of Science and Technology (Guangzhou). Its architecture is deceptively simple. Ultrathin manganese dioxide (MnO2) nanosheets, roughly 84 nanometers across and a mere 1.5 nanometers thick, are first decorated with a polyethylene glycol derivative and then loaded with R848, a small-molecule agonist of Toll-like receptors 7 and 8 that acts as a potent immunological adjuvant. The drug loading reached an impressive 35.70 percent at an optimized feed ratio, held in place by a combination of Mn–N coordination bonds, pi–pi stacking interactions, and hydrophilic–hydrophobic forces mediated by the amino groups on the polymer coating.

The final and arguably most clever step is the camouflage. The researchers extracted membranes from 4T1 mouse breast cancer cells through repeated freeze–thaw cycles and co-extruded them with the drug-loaded nanosheets through a polycarbonate filter, producing particles cloaked in an authentic tumor-cell shell. Protein electrophoresis confirmed that the banding pattern of the coated particles matched that of the 4T1 membranes and was clearly distinct from membranes of 3T3 normal fibroblasts, which served as an irrelevant-membrane control. After coating, the particles grew to about 170 nanometers in lateral dimension and 15 nanometers in thickness, acquired a more negative surface charge that favors stable transport in blood, and remained well dispersed in simulated body fluids, with sizes consistently below 200 nanometers.

That disguise pays off in targeting. When the team labeled the particles with the fluorescent dye coumarin 6 and incubated them with 4T1 cancer cells, fluorescence inside the cells surged within the first hour and plateaued by about six hours, while normal 3T3 cells took up far less material. In living mice bearing 4T1 tumors, the membrane-coated particles accumulated in tumors progressively after intravenous injection, peaking at twelve hours — at which point tumor fluorescence was a striking 73.27-fold higher than in mice injected with free dye. Crucially, a biodistribution comparison showed that particles coated with 3T3 membranes showed no tumor enrichment, demonstrating that the homing is specifically mediated by the tumor-cell membrane’s own adhesion molecules rather than by any generic membrane effect.

Once the particles arrive, the tumor’s own chemistry triggers the payload. The tumor microenvironment is weakly acidic, and this acidity dissolves MnO2. In vitro release experiments showed that at pH 7.4, mimicking blood, less than 20 percent of R848 escaped over twelve hours, but at pH 5.0 roughly 45 percent was released within the first half hour and about 77 percent within three hours. This pH-gated behavior means the adjuvant stays locked up during circulation and is dumped only where it is needed — inside the tumor.

The therapeutic logic then unfolds in several reinforcing layers. MnO2 catalyzes the decomposition of hydrogen peroxide, which tumors overproduce, into oxygen, directly relieving the hypoxia that makes tumors resistant to radiation. Under X-ray irradiation, the released manganese ions amplify reactive oxygen species generation and deplete glutathione, the cell’s antioxidant shield. In cultured 4T1 cells treated with a 6 Gy radiation dose, the combination reduced viability by roughly 20 percent beyond radiation alone, produced the strongest signals of DNA double-strand breaks as measured by gamma-H2AX staining, and drove the highest levels of apoptosis. Immunohistochemical staining of treated tumors for HIF-1alpha, a master regulator of the hypoxic response, was markedly reduced in mice receiving the full combination, confirming that hypoxia relief operates in vivo as well.

Radiation’s second, subtler gift is immunogenic cell death, in which dying tumor cells hoist danger flags — calreticulin on their surface, and ATP and HMGB1 released outside — that alert the immune system. The combination of MnO2–R848@CM and radiation produced the greatest calreticulin translocation, the lowest residual nuclear HMGB1, and the highest ATP release in cultured cells. These damage signals then act on dendritic cells, the sentinels of adaptive immunity. In mouse bone-marrow-derived dendritic cells, MnO2 alone raised maturation marker expression (CD80/CD86) from 59.2 to 76.2 percent, R848 alone to 78.0 percent, and the combination performed even better, while also driving robust secretion of the inflammatory cytokine TNF-alpha. In a Transwell system separating irradiated tumor cells from dendritic cells, the full combination pushed dendritic cell maturation to 77.5 percent, far above radiation alone. Mechanistically, manganese ions are known to accelerate the DNA-sensing enzyme cGAS and strengthen the binding of its product, cGAMP, to the STING adaptor, triggering type I interferon production — a pathway the team confirmed was activated in the treated dendritic cells.

The in vivo results were dramatic. In 4T1 tumor-bearing mice given a single injection followed by three radiation sessions, the membrane-coated platform combined with radiation achieved a tumor growth inhibition rate of 92.30 percent, with some mice showing complete tumor ablation. Tumor sections revealed the most extensive necrosis, the most apoptotic cells, and the strongest suppression of the proliferation marker Ki67 in the combination group, and immunofluorescence showed the greatest infiltration of CD8-positive cytotoxic T cells — the effector arm that can recognize tumor antigens and kill malignant cells throughout the body. Safety profiles were reassuring: treated mice maintained stable body weight, blood chemistry markers of liver and kidney function showed no significant deviations, and histology of major organs revealed no pathological changes or inflammatory infiltration.

The authors are candid about the work’s limits and its promise. They observed a degree of what they call synergistic overflow, in which the fully combined treatment did not always deliver benefit clearly beyond its individual components while adding preparation complexity, and they note that the tumor membrane itself may carry adjuvant properties that remain to be explored. They also point toward the clinic’s hardest problem: primary resistance to immune checkpoint inhibitors. By relieving hypoxia, inducing immunogenic cell death, activating cGAS–STING, and ferrying R848 into tumors to mature dendritic cells and recruit CD8-positive T cells, the platform could, in principle, convert immunologically cold tumors into hot ones and sensitize them to anti-PD-1 or anti-PD-L1 therapy — a hypothesis the team plans to test directly. For now, the study stands as a vivid demonstration that a nanoparticle wearing a tumor’s own face can carry an immune alarm clock deep into hostile territory, set it to go off under radiation, and leave the immune system to finish the job.

Subject of Research: A cancer-cell-membrane-coated MnO2 nanoplatform delivering the R848 adjuvant to enhance radio-immunotherapy of breast cancer

Article Title: Cancer-cell-mimicking MnO 2 nanoplatform delivers immunological adjuvants to enhance radio-immunotherapy

Article References: Zhang, Z., Liu, P., Zeng, W., Huang, C., Wang, S., Guan, S., Duan, Y., Wu, D., Zhao, Y., & Wu, J. (2026). Cancer-cell-mimicking MnO2 nanoplatform delivers immunological adjuvants to enhance radio-immunotherapy. Materials Today Bio, 41, Article 103720. https://doi.org/10.1016/j.mtbio.2026.103720

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103720

Keywords: MnO2 nanosheets, cancer cell membrane coating, R848, radio-immunotherapy, cGAS-STING pathway, immunogenic cell death, tumor hypoxia, dendritic cell maturation, CD8 T cells, breast cancer, biomimetic nanoparticles, drug delivery

The core idea is deceptively simple: if the immune system clears foreign nanoparticles before they can do their work, disguise them as something the body already tolerates. The most extensively studied disguise is the red blood cell membrane. Human erythrocytes circulate for roughly 120 days, largely because they display CD47, a surface protein that transmits a “don’t eat me” signal to macrophages, along with band 3 and glycophorins that suppress opsonization and complement activation. When nanoparticles are cloaked in RBC membrane, they inherit these properties, dramatically extending circulation half-life and protecting encapsulated mRNA or peptide antigens from serum nucleases and proteases. Hybrid RBC-lipid nanoparticle platforms have shown improved mRNA protection, prolonged antigen expression, and enhanced dendritic cell uptake, while RBC-coated PLGA particles loaded with tumor peptides have generated stronger cytotoxic T lymphocyte responses in preclinical tumor models.

Exosomes, the nanoscale vesicles between 30 and 150 nanometers that cells naturally secrete to communicate with one another, offer a second biomimetic strategy with a different immunological personality. Their membranes carry tetraspanins and integrins that promote selective uptake by dendritic cells, and their origin matters enormously. Tumor-derived exosomes ferry a broad repertoire of tumor-associated antigens and neoantigens that mirror the parental tumor, but they can also smuggle immunosuppressive cargo such as PD-L1, TGF-beta, and regulatory microRNAs that blunt T-cell responses. Dendritic cell-derived exosomes, by contrast, come pre-loaded with MHC-peptide complexes and CD80/CD86 co-stimulatory molecules capable of priming both CD4 and CD8 T cells without requiring live dendritic cells. The catch is manufacturing: donor heterogeneity, variable cargo composition, and purification methods that differ wildly in yield and purity make GMP-grade standardization a formidable barrier.

Fully synthetic coatings sidestep some of that unpredictability. Artificial lipid bilayers and polymer shells can be tuned for antigen density, ligand spacing, endosomal escape, and release kinetics, and they can be functionalized with mannose for dendritic cell targeting, TLR agonists such as CpG or MPLA for innate activation, or checkpoint modulators like anti-PD-1 peptides. pH-sensitive and enzyme-responsive linkers now allow cargo release triggered by the acidic, enzyme-rich tumor microenvironment itself. Perhaps most striking are artificial antigen-presenting cells, polymeric scaffolds displaying MHC-I-peptide complexes and co-stimulatory ligands, which have outperformed natural dendritic cells at activating antigen-specific CD8 T cells both in vitro and in vivo. Hybrid systems that combine RBC membranes with exosomal or tumor-derived components aim to capture the best of both worlds: long circulation plus tumor homing and cross-presentation.

On the payload side, the review distinguishes two complementary modalities. Peptide nanovaccines deliver defined tumor epitopes chosen for strong MHC binding and minimal expression in healthy tissue, with neoantigens prioritized over shared antigens to avoid central tolerance. The authors’ own prior work illustrates the approach: survivin epitope variants delivered in PLGA nanoparticles drove potent CTL responses, BCMA peptide-loaded nanoparticles enhanced dendritic cell delivery in multiple myeloma models, and STEAP peptide nanovaccines inhibited tumor growth in vivo. mRNA nanovaccines take the opposite tack, encoding full-length antigens or multiple epitopes so that dendritic cells manufacture the antigen themselves, activating both CD4 and CD8 arms. Because mRNA does not integrate into the genome and carries intrinsic adjuvanticity through TLR3, TLR7/8, and RIG-I sensing, it offers a favorable safety profile, though poor endosomal escape and dose-dependent inflammation remain stubborn bottlenecks.

The COVID-19 pandemic supplied an unplanned clinical laboratory for these questions. The global mRNA-LNP rollout revealed that reactogenicity is dose-dependent, driven by innate recognition of ionizable lipids and mRNA structures, and that maximal inflammation does not equal optimal immune priming. Subtle structural differences in ionizable lipids markedly alter endosomal escape, biodistribution, and cytokine induction. For oncology, where patients are often immunosuppressed with altered pharmacokinetics, these lessons argue for individualized dose optimization, careful immune monitoring, and lipid engineering tailored specifically to cancer vaccination rather than borrowed wholesale from infectious disease.

Personalization is where the field is converging. Next-generation sequencing, mass spectrometry-based immunopeptidomics, and AI-guided epitope prediction now allow neoantigen discovery pipelines that move from tumor biopsy to individualized vaccine design in clinically relevant timelines. Autologous platforms go further, using patient-derived RBC, leukocyte, tumor cell, or exosome membranes so that even the nanoparticle surface reflects the patient’s biology, with tumor membrane coatings enabling homotypic binding to the originating cancer. The clinical signal is already visible: in the phase II KEYNOTE-942 trial, the personalized mRNA vaccine mRNA-4157 combined with pembrolizumab reduced recurrence risk by 44 percent and extended median progression-free survival from 16 to 23 months in resected high-risk melanoma, while BioNTech’s BNT111, targeting four melanoma-associated antigens, has demonstrated induction of both new and boosted pre-existing T-cell responses, albeit with a modest objective response rate that underscores interpatient variability.

Combination strategies may prove decisive. Biomimetic nanovaccines can prime T cells before checkpoint blockade, and sequencing studies suggest priming before PD-1 or CTLA-4 inhibition consistently outperforms simultaneous delivery. Co-delivery of antigens with TLR7/8, TLR9, or STING agonists within the same vesicle synchronizes innate and adaptive activation, while macrophage-targeted formulations can repolarize immunosuppressive M2 tumor-associated macrophages toward a pro-inflammatory M1 phenotype. Radiotherapy adds another layer, inducing immunogenic cell death that releases tumor antigens and damage-associated molecular patterns, activating the cGAS-STING pathway, and in rare but increasingly frequent cases producing abscopal responses in which nanovaccine-amplified immunity attacks metastases far from the irradiated site.

The translational obstacles are nonetheless sobering. Every personalized batch requires individualized sequencing, formulation, and quality control under time pressure dictated by fast-growing tumors. Patient-derived materials resist standardization, regulatory classification is murky because these products straddle biologics, cell therapies, and devices, and cold-chain logistics complicate distribution. The authors argue that modular microfluidic manufacturing, AI- and large-language-model-assisted neoantigen design, machine learning models that predict optimal nanoparticle physicochemistry, computer vision quality control, and digital twins of production pipelines could compress timelines and enforce batch consistency. Adaptive trial designs, including N-of-1 and Bayesian schemes, may be needed to evaluate vaccines that are by definition unique to each recipient, while immune-related response criteria replace conventional RECIST measurements that miss immunotherapy’s delayed kinetics.

What emerges from the review is a field in transition from clever chemistry to systems engineering. The mechanistic questions remain open, including how specific membrane compositions steer nanoparticles toward cross-presenting cDC1 dendritic cells versus degradative macrophage pathways, and which glycan signatures determine whether a coating stimulates or tolerizes. But the trajectory is clear: biomimetic coatings that borrow the body’s own camouflage, payloads scripted from each tumor’s mutanome, and AI-driven optimization loops that connect antigen discovery, formulation, manufacturing, and clinical feedback are converging into a unified platform. If the manufacturing and regulatory bottlenecks can be solved, the cancer vaccine may finally graduate from decades of sporadic promise into a routine pillar of precision oncology.

Subject of Research: Biomimetic and personalized nanovaccine platforms for cancer immunotherapy

Article Title: Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions

Article References: Xu, S., Yang, H., Minev, B., & Ma, W. (2026). Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions. Journal of Advanced Research, 88, 1137-1158. https://doi.org/10.1016/j.jare.2026.01.070

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.01.070

Keywords: nanovaccines, cancer immunotherapy, biomimetic nanoparticles, mRNA vaccines, neoantigens, red blood cell membrane, exosomes, lipid nanoparticles, immune checkpoint blockade, dendritic cells, personalized medicine, STING agonists

The core idea behind biomimetic nanomedicine is deceptively simple. Nanoparticles, whether synthetic or natural in origin, are coated with materials derived from living cells, such as membranes from platelets, macrophages, neutrophils, natural killer cells, erythrocytes, or even cancer cells themselves. Alternatively, they can be decorated with naturally derived biomolecules like monoclonal antibodies, viral capsids, and natural proteins, or with synthetic analogues such as targeting peptides and aptamers. This biological disguise confers several decisive advantages. The particles circulate in the bloodstream for longer periods, evade recognition by the reticuloendothelial system, accumulate preferentially in tumor tissue, and provoke far fewer unwanted immune reactions than conventional nanocarriers. In effect, the drug carrier stops looking like a foreign invader and starts looking like something the body already tolerates.

The review grounds this technological optimism in a detailed account of colon cancer biology. The disease typically unfolds over ten to twenty years through the well-characterized adenoma-carcinoma sequence. Loss of the APC tumor suppressor gene triggers uncontrolled proliferation and the formation of benign polyps. Subsequent activation of the KRAS oncogene drives growth into a large adenoma, while deletion of the DCC gene, involved in cell adhesion and apoptosis, permits abnormal cells to invade neighboring tissue. The final transformation comes with loss of p53, the guardian of DNA repair and programmed cell death, after which cells accumulate further mutations, breach the basement membrane, and metastasize to organs such as the liver and lungs. Understanding this stepwise molecular progression, the authors argue, is essential for designing nanocarriers that intervene at the right biological moment.

Among the most striking platforms described in the review are cell membrane-coated nanoparticles. By wrapping a synthetic drug-loaded core in the membrane of a red blood cell, platelet, or immune cell, researchers inherit the surface chemistry of that cell, including its complement-regulating proteins and adhesion molecules. Preclinical work highlighted in the review illustrates the potential vividly. In a mouse model of inflammation-driven colorectal cancer, biomimetic PLGA nanoparticles coated with red blood cell membranes and loaded with the enzyme shikimokinase produced stable body weights, reduced disease activity scores, longer colons, fewer tumor nodules, restored crypt architecture on histology, and enhanced apoptosis of tumor cells as measured by TUNEL staining. The membrane-coated formulations outperformed their uncoated counterparts across every endpoint, a result the authors present as evidence that biomimicry is not merely cosmetic but functionally therapeutic.

Exosome-based carriers represent a second major pillar. Exosomes are naturally occurring extracellular vesicles that cells use to communicate, and their innate ability to cross biological barriers makes them attractive delivery vehicles. Yet the review is candid about their limitations. Isolation methods such as ultracentrifugation, size-exclusion chromatography, and immunoaffinity capture yield heterogeneous populations with inconsistent purity, undermining reproducibility. Cargo loading through passive incubation, electroporation, or chemical transfection still suffers from low encapsulation rates and rapid release. Once injected, exosomes face rapid clearance, aggregation, and degradation in circulation. Engineering strategies, including genetic modification of donor cells to display tumor-targeting peptides on the exosome surface, offer improved intrinsic targeting, while surface functionalization provides greater flexibility and scalability. The authors call for systematic studies of drug loading, release kinetics, and therapeutic efficacy to establish the standardized protocols that clinical translation will demand.

Inorganic and metal-based nanoparticles form a third, chemically diverse family. Gold nanoparticles, ranging from one to one thousand nanometers and available in spherical, rod, star, and cage morphologies, can convert near-infrared light into heat, making them potent agents for photothermal therapy. In one study cited in the review, photostable gold nanoparticles averaging roughly 180 nanometers were absorbed by colon cancer cells, as confirmed by increased cellular granularity, and produced a dramatic drop in cell viability after treatment. Silver nanoparticles take a different route, generating reactive oxygen species that induce oxidative stress, mitochondrial damage, membrane rupture, and apoptosis. Research on the SW480 colon cancer cell line showed that silver nanoparticles functionalized with glutamine and conjugated with thiosemicarbazide triggered apoptosis through notable caspase activation and downregulation of the HULC long non-coding RNA and the PPFIA4 oncogene. Silver nanoparticles can also enhance the tumor accumulation of conventional drugs like doxorubicin while reducing toxicity to healthy tissue, and their strong light-scattering properties make them useful as contrast agents in dark-field microscopy and surface-enhanced Raman scattering.

The review also catalogs the contributions of softer organic platforms. Dendrimers, tree-like branched macromolecules whose size and surface chemistry are controlled generation by generation, can be loaded with drugs in their interior cavities or conjugated to their periphery. Fourth-generation PAMAM dendrimers carrying capecitabine shrank tumors in mouse models with fewer effects on blood and liver than the free drug, while pegylated PAMAM dendrimers decorated with AS1411 anti-nucleolin aptamers showed heightened sensitivity against HT29 and C26 colorectal cancer cells and efficacy in tumor-bearing mice. A fifth-generation L-lysine dendrimer modified with polyoxazoline improved the therapeutic index of SN-38, the active metabolite of irinotecan, by controlling drug release and extending circulation time. Liposomes, the oldest clinical nanomedicine platform, continue to evolve: FDA-approved formulations such as Doxil and DaunoXome established the field in the 1990s, and temperature-sensitive liposomal doxorubicin, known as Thermodox, delivered twenty-five times more drug to cancer cells than standard intravenous delivery in preclinical testing for colorectal liver metastases.

Carbon nanotubes and quantum dots round out the arsenal. Carbon nanotubes, cylindrical rolls of hexagonally bonded carbon atoms a few nanometers in diameter, penetrate plasma membranes readily thanks to their needle-like shape and vast surface area. Combining single-walled carbon nanotubes with the TRAIL protein increased the death rate in colorectal cancer cell lines roughly tenfold, and carboxylic acid functionalization exploits the acidic lysosomal environment of cancer cells, around pH 5.5 versus 7.4 in healthy tissue, to trigger pH-dependent drug release. Quantum dots, semiconductor particles smaller than ten nanometers, offer exceptional fluorescence and photochemical stability for bioimaging, and carbon quantum dots are emerging as diagnostic and therapeutic tools in their own right. The review notes that colon cancers frequently overexpress placenta-specific protein 1, providing a molecular anchor for targeted nanoparticle binding.

The translational picture is genuinely encouraging but far from settled. The review catalogs a growing roster of clinical trials involving nanotechnology in colon and gastrointestinal cancers, including studies of cetuximab-loaded nanoparticles, liposomal irinotecan combined with FOLFIRI and bevacizumab, liposomal mitomycin-C with capecitabine, and nanoliposomal irinotecan paired with TAS-102. Yet the authors are clear that major bottlenecks remain: scalable manufacturing, batch-to-batch reproducibility, and demanding regulatory pathways under FDA and EMA frameworks. Their proposed solutions include cost-effective microfluidic production, automated bioreactors, comprehensive protocols for exosome isolation and nanoparticle characterization, and early harmonization with regulatory safety and quality standards. Looking forward, they envision theranostic platforms that merge diagnosis and treatment in a single particle, biomimetic carriers that ferry gene-editing tools alongside chemotherapy, nanomaterials engineered to reprogram the tumor microenvironment, and the encapsulation of plant-derived phytochemicals to overcome their poor solubility and low bioavailability. If interdisciplinary collaboration can close the gap between laboratory proof-of-concept and clinical practice, the authors conclude, biomimetic nanomaterials could move colon cancer therapy decisively closer to being safer, more effective, and personally tailored.

Subject of Research: Biomimetic nanomaterials for targeted drug delivery in colon cancer

Article Title: Advances in biomimetic nanomaterials for targeted drug delivery in colon cancer

Article References: Dharme, K. K., Jain, P., Verma, G., & Uddin, A. (2026). Advances in biomimetic nanomaterials for targeted drug delivery in colon cancer. Holistic Integrative Oncology, 5(1), Article 58. https://doi.org/10.1007/s44178-026-00279-4

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00279-4

Keywords: colon cancer, biomimetic nanoparticles, drug delivery, exosomes, cell membrane coating, gold nanoparticles, silver nanoparticles, dendrimers, liposomes, carbon nanotubes, quantum dots, nanomedicine

The core insight behind the study is that soft tissue breakdown around implants is not simply a matter of insufficient attachment. Instead, the researchers describe an early pathogenic-immunological amplification loop. Staphylococcus aureus, a bacterium with a particular affinity for titanium surfaces, is among the first colonizers of a fresh implant. Its accumulation, combined with surgical trauma and implant-induced oxidative stress, drives macrophages into a dysfunctional, pro-inflammatory state. Sustained inflammatory signaling then damages fibroblasts, impairs extracellular matrix remodeling, and blocks vascular maturation, all of which undermine the connective tissue barrier that should protect the implant. Disrupting this loop, the authors reasoned, requires a therapy that can target both the bacterium and the stressed immune cells at the same time.

Their solution, called MoSe2@SPMM, is a two-layer construction. At its heart sits a molybdenum diselenide nanoflower, a member of the nanozyme family of artificial enzyme mimics. MoSe2 carries intrinsic multi-enzyme catalytic activity that scavenges reactive oxygen species, mimicking catalase, glutathione peroxidase, and superoxide dismutase. It also converts near-infrared light into heat efficiently, and the material’s molybdenum and selenium components are individually associated with favorable biocompatibility. Wrapped around this reactive core is a cell membrane shell harvested from macrophages that had been deliberately pre-stimulated with S. aureus. The coating is applied through ultrasonication and extrusion, leaving a continuous membranous shell visible in transmission electron microscopy around a particle roughly 218 nanometers in hydrodynamic diameter before coating.

The choice of a bacteria-stimulated membrane is the study’s most elegant twist. Proteomic profiling of macrophages after S. aureus exposure revealed 534 upregulated and 235 downregulated proteins, with enrichment overwhelmingly concentrated in bacterial recognition, pattern-recognition-receptor signaling, and Toll-like receptor pathways. Follow-up transcriptional and protein analyses showed that TLR2, TLR6, and the scavenger receptor CD36 were selectively upregulated on the macrophage membrane, while virus-associated receptors stayed flat. When these membranes were transferred onto MoSe2, Western blots confirmed the nanoparticles retained elevated levels of all three recognition molecules. The result is a nanoparticle dressed in a molecular disguise that bacteria find irresistible to bind, and one that other macrophages recognize as kin.

Laboratory testing bore out the dual-targeting hypothesis. Compared with nanoparticles coated in unstimulated macrophage membranes, red blood cell membranes, or synthetic DOPC lipid shells, MoSe2@SPMM showed dramatically stronger binding to S. aureus in both scanning electron and confocal microscopy, while showing no such preference for E. coli, a sign of genuine selectivity. When near-infrared light at 808 nanometers was applied, the bound particles converted light to heat at the bacterial surface, producing what the authors call targeted contact-enhanced photothermal killing. Bacterial membranes roughened, perforated, and collapsed, and colony assays showed the treatment dramatically outperformed controls. Against biofilms, which are far more resistant and clinically relevant, the particles not only suppressed formation but also disrupted established structures, killing bacteria throughout the biofilm depth rather than only at the surface.

The second axis of action operates inside immune cells. Because the coating carries homotypic recognition features, MoSe2@SPMM is preferentially internalized by macrophages themselves, while fibroblasts and endothelial cells take up far less of it. Once inside oxidative-stress-injured macrophages, the nanoparticle’s enzymatic core mops up excess reactive oxygen species. In vitro, the particles removed roughly 75 to 88 percent of hydrogen peroxide within an hour at moderate concentrations, generated dissolved oxygen, and quenched both superoxide and hydroxyl radicals in electron spin resonance assays, with activity persisting over repeated catalytic cycles. In cells, treatment lowered intracellular ROS, restored mitochondrial membrane potential, suppressed the pro-inflammatory marker iNOS, revived the repair-associated marker Arg-1, and shifted the secretome away from TNF-alpha and IL-6 toward IL-10 and TGF-beta.

Those cellular changes rippled outward to the tissue-building cells that determine whether a soft tissue seal can form. Conditioned medium from MoSe2@SPMM-treated macrophages restored the proliferation, migration, and tube-forming capacity of vascular endothelial cells under oxidative stress, accompanied by recovered expression of VEGF-A and FGF2, two master regulators of angiogenesis. Fibroblasts responded similarly, regaining migration and adhesion while rebuilding focal adhesion protein vinculin, fibronectin 1, and both collagen I and collagen III, the structural foundation of the peri-implant connective tissue. Biosafety testing was reassuring: the particles were compatible with cells up to 200 micrograms per milliliter, caused negligible hemolysis, and produced no histological, hematological, or liver and kidney abnormalities in treated animals.

The decisive test came in a rat maxillary implantation model in which S. aureus was inoculated at the peri-implant site to simulate early post-surgical stress. Under localized near-infrared irradiation, MoSe2@SPMM reduced the peri-implant bacterial burden by 91.4 percent, substantially outperforming both control coatings. Immunofluorescence at day 7 showed a marked shift in macrophage identity, with fewer iNOS-positive pro-inflammatory cells and more Arg-1-positive repair-associated cells. By day 28, the treated implants displayed denser alpha-SMA-positive vascular maturation, a 1.7-fold increase in peri-implant connective tissue width, 67.1 percent greater collagen deposition with better fiber organization, 61.4 percent higher integrin expression at the tissue-implant interface, and a 2.3-fold increase in angiogenesis. The animals developed a continuous epithelial barrier and reduced inflammatory infiltration, hallmarks of robust soft tissue integration.

What distinguishes this platform from conventional implant surface engineering is its mode of delivery and breadth of function. Surface-bound coatings fight a losing battle against the oral environment, gradually losing bioactivity and offering only single-function protection. MoSe2@SPMM, by contrast, is designed for local administration at the implant-soft tissue interface, potentially injected around the transgingival neck during early healing or under high-risk inflammatory conditions, then activated with intraoral near-infrared probes. The authors also suggest the design principle could extend beyond dentistry to orthopedic and percutaneous devices, wherever bacterial colonization, oxidative stress, and dysregulated inflammation jointly sabotage tissue repair.

Challenges remain before clinical translation. The rat model used controlled S. aureus inoculation rather than the polymicrobial biofilms characteristic of established human peri-implantitis, so real-world efficacy will need confirmation in more complex settings. Optimal treatment windows, irradiation parameters, repeat dosing schedules, and scalable membrane-coating manufacturing all require refinement. Yet the conceptual achievement is clear: by teaching a nanoparticle to hunt one specific bacterium and simultaneously nurse the immune cells back to health, the researchers have demonstrated that targeted antibacterial action and redox-mediated immune regulation can be fused into a single therapy, offering a genuinely new strategy for protecting the fragile seal on which every dental implant ultimately depends.

Subject of Research: Dual-targeted biomimetic MoSe2 nanozymes coated with S. aureus-stimulated macrophage membranes for enhancing peri-implant soft tissue integration

Article Title: Dual‐Targeted Biomimetic MoSe2 Nanozymes for Enhancing Peri‐Implant Soft Tissue Integration

Article References: Zhou, M., Tian, M., Yu, J., Kang, J., Chen, M., Yuan, Y., Liu, L., & Wei, H. (2026). Dual‐Targeted Biomimetic MoSe 2 Nanozymes for Enhancing Peri‐Implant Soft Tissue Integration. Advanced Science, Article e77771. https://doi.org/10.1002/advs.77771

Image Credits: AI Generated

DOI: 10.1002/advs.77771

Keywords: MoSe2 nanozymes, peri-implantitis, soft tissue integration, biomimetic nanoparticles, cell membrane coating, Staphylococcus aureus, photothermal therapy, macrophage reprogramming, reactive oxygen species, dental implants, immunomodulation, oxidative stress